Bio-Gate AG (XTER:BIG1) Risk Assessment

View and export this data going back to 2006. Start your Free Trial

What is Bio-Gate AG Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Bio-Gate AG is: High Risk: High uncertainty.

Competitive Comparison of Bio-Gate AG's Risk Assessment

For the Medical Instruments & Supplies subindustry, Bio-Gate AG's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bio-Gate AG's Risk Assessment Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bio-Gate AG's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Bio-Gate AG's Risk Assessment falls into.

Bio-Gate AG (XTER:BIG1) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Bio-Gate AG Risk Assessment Related Terms

Thank you for viewing the detailed overview of Bio-Gate AG's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Bio-Gate AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bio-Gate AG (XTER:BIG1) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

BIG1:Germany BIG1:Germany

Address

Neumeyerstraße 28-34, Nürnberg, DEU

Website

http://www.biogate.de

Bio-Gate AG is a Germany based medical technology company. The company employs silver technology to endow materials and products with antimicrobial properties. It is focused on the medical technology products portfolio. In addition, its technologies are also used to refine cosmetics, consumer goods, and industrial products. The products of the company are plasma-coating, additives, textile solutions, spray, masterbatches, and others. The organization uses two different technologies; first, silver particles are incorporated into cosmetics, paints, veneers or plastics, and second involve coating final products like implants or wound dressings with a silver-containing functional layer.

Executives

Karl Richter

Supervisory Board

Bio-Gate AG Headlines

No Headlines